Historical pm News Stories
Philip Morris International's ZYN Nicotine Pouches Receive FDA's Modified Risk Order
FDA grants modified risk status to PMI's ZYN nicotine pouches, marking a significant milestone.
FDA Approves ZYN Nicotine Pouches as Reduced-Risk Product, Impacting Philip Morris International
FDA approves ZYN as reduced-risk product, boosting Philip Morris stock.
Philip Morris Q1 Beat FDA Delays Pressure PM Drop!
Philip Morris reported a stronger-than-expected Q1 with solid smoke‑free growth and reaffirmed full‑year guidance, but FDA review delays for nicotine‑pouch products and notable insider selling weighed on PM stock, causing a near 5% pullback. The company maintains a steady dividend and a dual revenue engine of high‑margin smoke‑free offerings plus cigarette pricing power.
PM Stock Falls on FDA Delay, Japan Tax Headwinds!!
Philip Morris (PM) slid nearly 5% after reports of FDA slowdowns on nicotine-pouch approvals and fresh Japan tobacco taxes. Despite short-term technical weakness and regulatory pressure, analyst ratings remain largely positive with meaningful upside in price targets. Investors should monitor approval timelines, regional tax developments, and upcoming earnings for clarity.
Philip Morris Q1 Gains; Japan Tax Headwinds, PM Q2
Recent concrete developments — a white paper that pressured shares, solid Q1 2026 revenue and heated-tobacco growth, and scheduled Japanese excise-tax hikes — create measurable near-term headwinds for Philip Morris (PM) while underscoring the company’s long-term smoke-free transition.
PM Stock Slumps After FDA Delays ZYN Ultra Rollout
Philip Morris shares plunged after the FDA delayed approval of ZYN Ultra, triggering a one-day drop near 6% and amplifying concerns about the company’s smoke-free growth trajectory. Analysts remain cautiously optimistic, but near-term regulatory and competitive pressures have increased investor scrutiny.
Philip Morris: Smoke-Free Gains, Japan Tax Risk
Philip Morris reported strong smoke-free growth—EPS up double digits and smoke-free products now over 41% of revenue—but near-term headwinds from Japan excise hikes and ZYN inventory normalization could pressure PM stock in the S&P 500.
Philip Morris PM: Smoke-Free Growth vs BAT's Velo!
Philip Morris reported strong smoke-free revenue and margin expansion while British American Tobacco's Velo posted a sharp U.S. sales surge. Elevated trading volumes and recent guidance make PM stock sensitive to competitive and regulatory catalysts — here are the key facts and investor takeaways from the past week.
Philip Morris: Smoke-Free Surge Powers Q4 Beat Now
Philip Morris delivered stronger-than-expected Q4 and full-year results driven by rapid adoption of smoke-free products, while regulatory progress on ZYN and persistent cost pressures will be key near-term catalysts for PM stock.